AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06210763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Threshold IMT and traditional physical therapy program
Description: twenty ICU-acquired weakness elderly patients will receive chest physiotherapy (cough training, vibration, percussion, rib springing, and postural drainage), 30 minutes of resisted training on upper- and lower-limb muscles (15 min on upper limb and 15 min on lower limb), and 30 minutes of neuromuscular electrical stimulation of lower- and upper-limb muscles (triceps and wrist extensors, dorsiflexors, and quadriceps). sessions will be executed 5 times weekly). this Group will receive 3-set IMT (two sessions daily via threshold IMT, the set contain 10 repetitions) 5 times weekly. The study duration will be 1 month.
Study NCT06131528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation Breathing Exercises Group
Description: This group will preform Relaxation Breathing Exercises that includes Slow Deep Breathing, Pursed lip Breathing, Deep Diaphragmatic Breathing and Alternate Nostril Breathing
Study NCT06131528 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group
Description: The control group received lifestyle modifications that are an important part of hypertension management
Study NCT06210763 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditional physiotherapy program
Description: twenty ICU-acquired weakness elderly patients will receive chest physiotherapy (cough training, vibration, percussion, rib springing, and postural drainage), 30 minutes of resisted training on upper- and lower-limb muscles (15 min on upper limb and 15 min on lower limb), and 30 minutes of neuromuscular electrical stimulation of lower- and upper-limb muscles (triceps and wrist extensors, dorsiflexors, and quadriceps). sessions will be executed 5 times weekly).
Study NCT05471258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: monopolar dielectric diathermy
Description: The Experimental Group formed by 30 subjects will undergo an application of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device developed by the electro-medicine company Biotronic Advance Develops SL, on the lumbar muscles by means of rotary movements and translation, adapting to the muscle fibers of the lumbar area. A pulsed emission of 840 KHz and 30v will be made dynamically during a treatment time of 20 minutes. 3 weekly sessions will be performed for 3 weeks, a total of 9 treatment sessions.
Study NCT05471258 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control: Placebo
Description: The 30 participants in the control group will receive a placebo treatment, consisting of the same execution protocol as the EG, but with a non-emitting device whose software and hardware will be exactly the same as that used in the EG. The intervention will be simulated for 20 minutes.~3 weekly sessions will be held for 3 weeks, a total of 9 treatment sessions.
Study NCT05299879 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test, NT-proBNP, Echocardiography, 6 minute walk test, Right heart catheterization
Description: Screening for advanced HF with modified criteria from the Heart Failure Association of the European Society of Cardiology
Study NCT06270420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technological Motor Rehabilitation
Description: Patients will undergo to motor treatment in the HoSmartAI room using one of the technological devices (i.e. OAK, VRRS Evo by Khymeia Group, Padova, Italy; AMADEO, PABLO by Tyromotion GmbH, Gratz, Austria), for the upper limb and lower limb motor recovery, balance and manual dexterity recovery. The duration of the treatment will be 15 sessions, 1 hour each, with daily frequency, 5 days a week, for a total of 3 weeks.
Study NCT05232734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine Citrate 20 MG/ML Oral Solution
Description: Caffeine syrup will be prepared by pharmacy laboratory and kept refrigerated (2-8C), to be used within 1 month from the date of preparation by pharmacy laboratory.
Study NCT06430528 — intervention group
Intervention type: DRUG
Intervention: Osilodrostat
Description: Add methylprednisolone to osilodrostat therapy after first dose and continue during osilodrostat titration.
Study NCT06656325 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia® FX405
Description: Procedure administrations with the Erchonia® FX-405 will be applied eight times during the 5-month procedure administration phase. Phase One involves one procedure administration each week for 4 consecutive weeks. Phase 2 commences for one month following the completion of Phase One and involves one procedure administration each month for the next four consecutive months. Each procedure administration with the Erchonia FX405 takes 10 minutes and will be administered by the test site.~Additionally, subjects will receive Scaling and Root Planing (SRP) prior to the administration of the first procedure with the Erchonia FX405, and a second time at the 3-month study midpoint assessment visit.
Study NCT06656325 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: Procedure administration with the Placebo Laser (emitting non therapeutic light) will be applied eight times during the 5-month procedure administration phase. Phase One involves one procedure administration each week for 4 consecutive weeks. Phase 2 commences for one month following the completion of Phase One and involves one procedure administration each month for the next four consecutive months. Each procedure administration with the Placebo Laser takes 10 minutes and will be administered by the test site.~Additionally, subjects will receive Scaling and Root Planing (SRP) prior to the administration of the first procedure with the Placebo Laser, and a second time at the 3-month study midpoint assessment visit.
Study NCT06656611 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HPV self sampling
Description: Selected women will perform a vaginal self-sampling using a swab
Study NCT06655961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Garden Activities Program
Description: When we look at the studies evaluating the effect of gardening activities on hospitalized children; it is seen that mostly children's opinions about therapeutic gardens are included and studies involving active gardening activities are limited. Shao et al. (2020) gave hospitalized children a task about garden plants and made them full this task through active participation and mobile games. However, it is seen that the gardening activity applied in this study was limited to a 5-minute task. The most important difference of our study from these studies is that a standardized gardening activity program will be applied to hospitalized children during their hospitalization and the active participation of the child will be ensured.
Study NCT06655961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical routine treatment and nursing care protocol
Description: Within the scope of the clinic routine treatment and nursing protocol; the decision to hospitalize the child, orientation to the clinic, execution of hospitalization paperwork, room placement, invasive intervention and treatment procedures are carried out. Treatment and care hours are revised according to individual order characteristics; 08.00-20.00, 08.00-16.00-00.00, 06.00-12.00-18.00-00.00 are planned considering the time order. 13.00-15.00 are the visiting hours. The child is not allowed to leave the clinic except for any medical purpose. No intervention will be applied to the control group of this study until the discharge process takes place.
Study NCT06656533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated Transcranial magnetic stimulation (rTMS)
Description: Transcranial Magnetic Stimulation (TMS) involves a procedure where parts of the participants brain will be non-invasively (i.e. indirectly) stimulated by magnetic pulses. These magnetic pulses induce very brief activity in brain areas underlying the TMS coil. TMS will be performed by giving repetitive pulses (rTMS). rTMS has shown promise to reduce cortical hyperexcitability and to improve subjective measures of sleep quality and insomnia symptoms in patients with insomnia disorder. The goal of this study is to optimize the impact of rTMS therapy on sleep outcomes for patients with insomnia disorder.
Study NCT05912543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Titration of FiO2
Description: The inhaled oxygen concentration after one-lung ventilation will be treated by the group.
Study NCT04826757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinated care
Description: Coordinated care between general practioners; physiotherapists and occupational health services.~Early contact with occupational health service by the general practioner and use of occupational retention tool Active physiotherapy (Individual active, intensive and regular rehabilitation program with 15 sessions of 1 hour, at a rate of 2 or 3 sessions per week)
Study NCT06488768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radial nerve block
Description: Ultrasound-guided Radial nerve block. Conducted with 10 mL of Lidocaine 2%. Ultrasound image are stored for documentation.
Study NCT05597267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIRIA Laser
Description: 4-6 experimental treatments at 4-6 weeks intervals
Study NCT05292391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sm-p80
Description: The Sm-p80 protein is formulated and lyophilized to yield the vaccine antigen, Sm-p80 for Injection.
Study NCT05292391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sm-p80 + GLA-SE
Description: Combination vaccine containing Sm-p80 antigen and GLA-SE adjuvant.
Study NCT06697197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986482
Description: Specified dose on specified days
Study NCT06697197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab and rHuPH20
Description: Specified dose on specified days
Study NCT06697197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab/relatlimab/rHuPH20
Description: Specified dose on specified days
Study NCT06697197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Specified dose on specified days
Study NCT06692335 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity Focused Ultrasound (HIFU)
Description: The HIFU treatment will utilize the Haifu JC 200 system under real-time ultrasound guidance, with participants positioned prone in a water-filled generator chamber. Conscious sedation will be administered using fentanyl and midazolam, adjusted based on pain tolerance. Acoustic output power will range from 300 to 400W.
Study NCT06692335 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: myomectomy
Description: Laparoscopic or open or hysteroscopic myomectomy will be performed.
Study NCT05648474 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Somatosensory evoked potential [SSEP] intraoperative monitoring
Description: No study specific intervention is performed. Intraoperative neuromonitoring system that is observed in this study is for assessing the health of the lumbar plexus during lateral lumbar interbody fusion surgery
Study NCT06372717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-4098
Description: APL-4098 is administered orally in 28-day cycles
Study NCT06375941 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational
Study NCT06736821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Open sinus augmentation with melatonin gel mixed with xenograft
Description: All Patients in this group underwent open sinus procedures to lift the sinus membrane followed by application of the melatonin gel which was mixed with xenograft as an augmentation material.~Preclinical studies proved the direct action of melatonin in enhancing the differentiation and proliferation of bone-forming osteoblasts. In addition to increasing bone mass, melatonin also facilitates new bone growth and osteointegration, making melatonin a particularly attractive molecule for use in bone implants when used alone or in combination with other growth factors
Study NCT06736821 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open sinus augmentation with xenograft
Description: All Patients in this group underwent open sinus procedures to lift the sinus membrane followed by application of the xenograft as an augmentation material xenograft is used instead of autogenous bone graft to avoid the morbidity of the donor side
Study NCT06739876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable device-based intervention (with motivational support via social media)
Description: The wearable device-based intervention aims to reduce sedentary behavior as the Move alert function may facilitate the management of one's physical activity. Motivational support will be provided via an online community created using LINE platform. The platform serve for the following purposes: a) providing psychoeduation prior to the intervention; b) providing a place for participants to motivate and encourage each other; c) provide health knowledge to participants weekly, to motivate behavioral change; d) encouraging participants to upload their daily step count to the community page to motivate each other's progress; e) based on participant's performance, research assistants will provide tailored support using Line stickers designed for the present intervention; f) research assistants will monitor participants' step counts and provide prizes (vouchers) for those who had the most step counts and made the most improvements.
Study NCT06739876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable device-based intervention (without support)
Description: The wearable device-based intervention aims to reduce sedentary behavior as the Move alert function may facilitate the management of one's physical activity.
Study NCT06739031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEF Treatment
Description: PEF Energy ablation of lung tumors
Study NCT06737770 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osseointegrated surgery for transfemoral amputation
Description: osseointegrated surgery for transfemoral amputation
Study NCT06739161 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sintilimab combined with chemotherapy and local treatment
Description: Treatment Regimens~①Chemotherapy: Regimen follows guideline-recommended first-line therapy for advanced gastric cancer.~②Sintilimab (200 mg) is administered with chemotherapy every 21 days. Maintenance immunotherapy continues for up to 1 year after chemotherapy.~③Local Treatment: Performed during cycles 3-8 of immunochemotherapy. Radiotherapy is preferred, using a combination of high- and low-dose fractionation, tailored to tumor location, size, and proximity to critical organs.~Alternative local treatments, such as radiofrequency ablation or surgery, may be used if suitable.
Study NCT06739161 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab combined with chemotherapy only
Description: Treatment Regimens ①Chemotherapy: Regimen follows guideline-recommended first-line therapy for advanced gastric cancer.~②Sintilimab (200 mg) is administered with chemotherapy every 21 days. Maintenance immunotherapy continues for up to 1 year after chemotherapy.
Study NCT06738381 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital intervention and motivational counselling
Description: A single sesstion of motivational interviewing and access to a digital plattform for a six months period
Study NCT06738381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital intervention and motivational counselling
Description: A single sesstion of motivational interviewing and access to a digital plattform for a six months period
Study NCT04759547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: handheld ultrasound-assisted technique
Description: Ultrasound with 3D navigation function is used to determine the needle insertion point and the insertion angle.
Study NCT04759547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional palpation-guided technique
Description: The interspinous space is detected by palpation
Study NCT05411978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Idebenone+ placebo
Description: Participants will receive Idebenone 30 mg+ placebo 60 mg for 12 weeks.
Study NCT05411978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone
Description: Participants will receive Idebenone 90 mg for 12 weeks.
Study NCT05411978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo 90 mg for 12 weeks
Study NCT06372717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine and APL-4098
Description: Azacitidine is administered at the standard dose of 75mg/m2 on Day 1 - Day 7 of each 28-day cycle; APL-4098 is administered orally.
Study NCT05033002 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Labda Siku Moja stigma reduction intervention
Description: The Labda Siku Moja stigma reduction intervention is a tailored stigma reduction intervention for women living with HIV in Tanzania. It is comprised of five ethnodramas (video stories) culturally and linguistically relevant to the Tanzanian women living with HIV.
Study NCT05046288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual guided tours
Description: The intervention is a participatory art-based activity which consists in MMFA virtual guided tours. Each virtual guided tour is performed with a group of 6 to 7 participants. They meet online one time per week for a 30 to 45 min of a guided tour during a 3-month period. Each tour is different and supervised by a MMFA trained guide.
Study NCT05601713 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No cooling (control)
Description: Participants are exposed to 38°C, 35% relative humidity for 6 hours without cooling interventions (control condition). Drinking water is available ad libitum.
Study NCT05601713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower limb immersion
Description: Participants are exposed to 38°C, 35% relative humidity for 6 hours. For the last 40 min of each hour, participants lower limbs are immersed in cool water (\~20°C) up to the level of mid calf. Drinking water is available ad libitum.
Study NCT05601713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower limb immersion + neck cooling
Description: Participants are exposed to 38°C, 35% relative humidity for 6 hours. For the last 40 min of each hour, participants lower limbs are immersed in cool water (\~20°C) up to the level of mid calf. During limb immersion, a towel soaked in cool water (\~20°C) is placed around the participants neck. The towel is re-wet half way through the 40-min limb immersion. Drinking water is available ad libitum.
Study NCT06053814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-050/NCNP-03
Description: NS-050/NCNP-03 solution for IV infusion.
Study NCT06053814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NS-050/NCNP-03 placebo-matching solution for IV infusion.
Study NCT05402202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healing abutment with scan peg (Neoss implant system, Harrogate, England)
Description: 12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of healing abutment with scan peg
Study NCT05402202 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Customized healing abutment
Description: 12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of customized healing abutment fabricated by intraoral scanning by scan body
Study NCT06392438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CycloSPORINE Ophthalmic
Description: Unidose of Cequa provided without charge to the participant. 1 drop in each eye morning and evening.
Study NCT06392438 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: CycloSPORINE Ophthalmic
Description: Unidose of Cequa provided without charge to the participant. 1 drop in each eye morning and evening.
Study NCT06392438 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light
Description: Appropriate eye patches and IPL gel will be applied. 15 triggers per passage will be applied from the right temple to the left temple (7 shots from the right temple to the right nose wing, 1 on the nose bridge and 7 shots from the left nose wing to the left temple). 2 passage/session will be applied.
Study NCT06359600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10501 tablet
Description: Administered orally
Study NCT06392438 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Intense Pulse Light
Description: Appropriate eye patches and IPL gel will be applied. 15 triggers per passage will be applied with the plastic blocker mounted on the IPL prism from the right temple to the left temple (7 shots from the right temple to the right nose wing, 1 on the nose bridge and 7 shots from the left nose wing to the left temple). 2 passage/session will be applied.
Study NCT05288881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANX105
Description: Participants will receive single-ascending doses of ANX105 administered by IV infusion.
Study NCT05288881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo administered by IV infusion.
Study NCT06359600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT04732715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CaRE Course
Description: Participants will complete the CaRE Course over a 6-8 week time period. The curriculum of the CaRE course will include topics addressing caregiving for a PLWD during a pandemic, navigating the healthcare system for a PLWD, guiding and managing daily life, and self care.